Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

William Plovanic

Canaccord Genuity

Image: William Plovanic

William Plovanic joined Canaccord in 2007 as a managing director, medical technology equity research analyst. He has been a publishing sellside analyst with coverage of medical devices for over 18 years. Plovanic's areas of coverage include orthopedics, diabetes, obesity, wound care, neuro-technologies, dialysis, aesthetics and general surgery. He has won awards for both stock picking and earnings accuracy. He is a frequent presenter at medical and industry meetings. He graduated from Bradley University with a bachelor's degree in finance and is a Chartered Financial Analyst.




Recent Interviews

Medtech Shifts from High Gear into Overdrive: Canaccord’s William Plovanic (8/19/14) Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report, William Plovanic of Canaccord Genuity highlights investment opportunities in medtech companies with innovative products targeting high-impact areas such as obesity, diabetes and wound care.

What Will Boost Medtech Stocks? Look for a Better Mousetrap, Says William Plovanic (2/21/13) Growth in the medical technology industry may have slowed, and governmental hurdles may make the forecast gloomy, but value plays await the investor who understands how innovation can drive company stock prices upward. In this interview with The Life Sciences Report, William Plovanic, analyst and managing director with Canaccord Genuity, talks about his top names in medtech and why he believes investors need to take advantage of the slowdown now. He also ruminates on the potential effects of Obamacare's impending implementation.

Special Report from the ADA: William Plovanic Identifies Companies with Promising Diabetes Solutions, Prospects (6/21/12) Every year, top researchers and physicians meet at the American Diabetes Association Scientific Sessions. This year, Canaccord Genuity Analyst and Managing Director William Plovanic reported back on promising developments and what they could mean for the companies behind them. In this interview with The Life Sciences Report, he explains why he is so positive on the space in general and about certain companies in particular.

Recent Quotes

"MDXG provides better, faster and cheaper technology compared to current wound-care therapies." (8/19/14) MiMedx Group Inc. - William Plovanic, Canaccord Genuity More >

"MDXG has quickly become a top pick in the advanced wound care dermal substitute segment." (7/29/14) MiMedx Group Inc. - William Plovanic, Canaccord Genuity More >

"We believe EXAC stock is undervalued relative to its peers." (10/31/12) Exactech Inc. - William Plovanic, Canaccord Genuity More >

"We reiterate our Buy rating on SLTM." (8/13/12) Solta Medical Inc. - William Plovanic, Canaccord Genuity More >

"We believe EXAC is undervalued; a full product pipeline should drive continued growth." (8/1/12) Exactech Inc. - William Plovanic, Canaccord Genuity More >

"SLTM is one of the best value picks in medtech." (7/19/12) Solta Medical Inc. - William Plovanic, Canaccord Genuity More >

"We are projecting EXAC's worldwide hip business to be up 5% YOY." (7/17/12) Exactech Inc. - William Plovanic, Canaccord Genuity More >

"EXAC provides an attractive risk/reward profile." (7/12/12) Exactech Inc. - William Plovanic, Canaccord Genuity More >



Due to permission requirements, not all quotes are shown.